Every value below carries the sentence it was read from.
70 sources stand behind the page.
Field
Value
Cited text
Known as
Mitomycin
“standard infusion chemotherapy (including gemcitabine, mitomycin, epirubicin, etc.), dissolved in 50 mL of normal saline or glucose, and intravesical infusion chemotherapy for...” NCT05547516 ↗65
“Intravesicular therapy will consist of BCG, gemcitabine, mitomycin or a similar drug, depending on institutional standards and treating provider's discretion.” NCT04073160 ↗
“UGN-102 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation.” NCT03558503 ↗
“UGN-103 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation.” NCT06331299 ↗
“UGN-104 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation.” NCT06774131 ↗
“UGN-102 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation.” NCT05243550 ↗
“UGN-102 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation.” NCT05136898 ↗
“Patients will be treated with HIPEC using a single dose of Mitomycin 15mg/m2 and Cisplatin 50mg/m2 at 41-42 C for 90 minutes.” NCT02672865 ↗
“5FU 1000 mg/m2/day as 96 hour infusion days 1-5 and 29-33; Mitomycin 10mg/m2 days 1 and 29” NCT03018418 ↗
“40 mg mitomycin with 800,000 U rHuPH20 total volume of 40 mL instilled” NCT00782587 ↗
“This study will evaluate the efficacy and safety of UGN-104, a new formulation of UGN-101 (approved in the United States and Israel as JELMYTO \[mitomycin\] for pyelocalyceal...” NCT06774131 ↗
Known as
Mitomycin C
“This study therefore aims to evaluate the non-inferiority of HIPEC with mitomycin C 10 mg/m2 for 60 minutes versus HIEPC with mitomycin C 35 mg/m2 for 90 minutes.” NCT06513065 ↗5
“Standard treatment of squamous cell carcinoma of the anus (SCCA)is 5-fluorouracil (5FU) and mitomycin C (MMC) based chemoradiotherapy (CRT).” PMID 37315583 ↗Jun 2023
“compare concentrations of mitomycin C (MMC) in the human bladder wall after either passive delivery or electromotive administration (EMDA)” PMID 9041189 ↗Mar 1997
“Comparison of Subconjunctival 5-FU Injection and Mitomycin C for Treatment of Early Bleb Failure” NCT00644215 ↗
“Mitomycin C (MMC) and Bacillus Calmette-Guérin (BCG)” PMID 38842053 ↗Jun 2024
“Mitomycin C will be used as 20mg dry powder.” NCT05024734 ↗
Known as
MMC
“Standard treatment of squamous cell carcinoma of the anus (SCCA)is 5-fluorouracil (5FU) and mitomycin C (MMC) based chemoradiotherapy (CRT).” PMID 37315583 ↗Jun 20236
“compare concentrations of mitomycin C (MMC) in the human bladder wall after either passive delivery or electromotive administration (EMDA)” PMID 9041189 ↗Mar 1997
“doses of mitomycin C (MMC) for the treatment of pseudomyxoma peritonei.” NCT06513065 ↗
“mitomycin (MMC) in the treatment of superficial bladder cancer” NCT00782587 ↗
“Mitomycin C (MMC) and Bacillus Calmette-Guérin (BCG)” PMID 38842053 ↗Jun 2024
“The MTD of PIPAC combined with mitomycin (MMS) in the treatment of CRCPM” NCT07349043 ↗
Known as
UGN-101
“This study will evaluate the efficacy and safety of UGN-104, a new formulation of UGN-101 (approved in the United States and Israel as JELMYTO \[mitomycin\] for pyelocalyceal...” NCT06774131 ↗
Known as
UGN-102
ClinicalTrials.gov intervention name — accepted as the source's own labelNCT04688931 ↗
Known as
UGN-102 (mitomycin) for intravesical solution
“UGN-102 (mitomycin) for intravesical solution” NCT04688931 ↗2
“UGN-102 (mitomycin) for intravesical solution” NCT05243550 ↗
“UGN-102 (mitomycin) for intravesical solution” NCT03558503 ↗
Known as
UGN-104 (mitomycin) for pyelocalyceal solution
“UGN-104 (mitomycin) for pyelocalyceal solution” NCT06774131 ↗
Action
Inhibit
“causing cross-linking of DNA and inhibition of DNA synthesis” NCT03766425 ↗
Route
Intravenous
“Patients receive IV doxorubicin, mitomycin, and cisplatin over 3 hours once every 3 weeks” NCT00002993 ↗